Article Text

Download PDFPDF

E-037 Robotic transcranial doppler use aneurysmal subarachnoid hemorrhage: a safety and efficacy study
Free
  1. K Clare1,
  2. A Stein2,
  3. J Cooper2,
  4. C Gandhi2,
  5. C Bowers2,
  6. C Cole2,
  7. J Santarelli2,
  8. J Pisapia2,
  9. F Al-Mufti2
  1. 1New York Medical College, Valhalla, NY
  2. 2Neurology and Neurosurgery, Westchester Medical Center, Valhalla, NY

Abstract

Introduction/Purpose Transcranial doppler (TCD) is a bedside modality to rapidly assess the presence of vasospasm or stenosis of cerebral arteries. However, manual TCD requires a trained sonographer which may not be available in all healthcare settings. The LUCID TCD system aims to expedite and enhance TCD blood flow measurements through semi-autonomous acquisition. This study aims to evaluate the safety and feasibility of the LUCID TCD system for detection of vasospasm.

Materials and Methods Peak velocities of the middle cerebral arteries (MCA) were measured and a velocity greater than 120 cm/s was considered indicative of vasospasm. To determine feasibility, maximal MCA velocities from LUCID TCD were compared to computer tomography angiography, and the Cohen’s Kappa value was calculated to gauge the agreement between the two modalities. Safety was assessed through quantifying the number of complications with central venous lines (CVL) or external ventricular drains (EVD) attributable to the LUCID device.

Results Nine patients (average age = 66 yrs) with subarachnoid hemorrhages or aneurysms underwent a total of 21 LUCID TCDs to assess the MCAs for vasospasm. The autonomous motion of the LUCID TCD ultrasound transducers did not displace or impinge on CVLs/EVDs. Moreover, LUCID acquired maximum MCA velocities and angiography moderately agree with a Cohen’s Kappa value of 0.61 (p=0.005).

Conclusions This investigation demonstrates that LUCID TCD as a modality to probe for MCA vasospasm is a viable option as LUCID maximum MCA velocities and angiography are moderately congruent. Additionally, LUCID TCD is safe to use clinically as it poses minimal risk to a patient‘s CVL or EVD.

Disclosures K. Clare: None. A. Stein: None. J. Cooper: None. C. Gandhi: None. C. Bowers: None. C. Cole: None. J. Santarelli: None. J. Pisapia: None. F. Al-Mufti: None.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.